Latest Conference Articles

Eleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.

The combination of multiple independent factors minimized the impact of baseline stage for predicting locoregional recurrence (LRR) following neoadjuvant chemotherapy in patients with breast cancer.

Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.

The actress Angelina Jolie’s decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation—associated with an increased risk of breast and/or ovarian cancer—apparently sparked an “Angelina effect” on public health.

One of the first studies to prospectively examine women’s breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM), may be making this decision as result of high anxiety and fear of recurrence.

Women who received signed letters from their family physician along with scheduled postcard reminders are more likely to return for mammography screening than women who only received a postcard.

In the first large pediatric study of adding aprepitant to standard prophylaxis for CINV, researchers have found aprepitant to be significantly more effective than a comparator placebo-added regimen in preventing this complication in children.

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer (mCRC).

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline in LBM observed with placebo for patients with NSCLC.

A geographic analysis of trial results supporting the use of ramucirumab in gastric cancer showed that patients in the U.S. and other Western nations experienced similar survival gains as did their counterparts in two other regions of the world.

Treatment with regorafenib significantly improved overall survival (OS) and progression-free survival (PFS) in an Asian population of patients with previously treated metastatic colorectal cancer (mCRC).

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based (non-AC) moderately emetogenic chemotherapy (MEC).

Adding ruxolitinib (Jakafi) to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation.

NEPA, a treatment intended to control CINV that combines netupitant and palonosetron, demonstrated superior activity in complete response rates (from 0 to 120 hours) over oral palonosetron monotherapy.

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus.

An updated analysis of a phase III trial hints at a possible survival advantage for patients with radioactive iodine-refractory differentiated thyroid cancer treated with the tyrosine kinase inhibitor sorafenib.

Jedd D. Wolchok, MD, PhD, discusses an updated analysis presented at the 2014 ASCO Annual Meeting that looked at pembrolizumab (MK-3475) for patients with melanoma.

The anti-PD-1 humanized antibody pembrolizumab (MK-3475) has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive non–small cell lung cancer (NSCLC).

Adding necitumumab to standard of care with gemcitabine-cisplatin improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) of squamous histology.

Combining the pan-deacetylase inhibitor panobinostat with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.

SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.

The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.

The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses new data on immunotherapies for head and neck cancers.

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.

Phase I results presented in 2013 from a study combining ipilimumab with the anti-PD-1 antibody, nivolumab,1 showed a 40% objective response rate in 53 patients with advanced melanoma and a preliminary overall survival (OS) of 80%.